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http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2014, KaohsiuAbstract The aim of this study was to investigate the median long-term effects of positive sur-
gical margin (PSM) and other prognostic factors on biochemical recurrence-free survival, overall
survival, and biochemical failure in patients who underwent radical prostatectomy. Our study
included 121 patients with pT2-3N0 disease treated betweenMarch 2006 and August 2012. The pa-
tientswere divided into two groups: thosewith PSMand thosewith negative surgicalmargin (NSM).
We analyzed the age, clinical and pathological stages, preoperative and postoperative Gleason
scores, duration of the follow-up, adjuvant chemo-/radiotherapy, biochemical failure, biochem-
ical recurrence-free survival, and overall survival in these patients. PSM was found in 25 (20%) pa-
tients, whereas 96 patients had NSM. The median follow-up time was 46.6 months (range 12e72
months) for thePSMgroupand48.3months (range7e149months) for theNSMgroup. Thebiochem-
ical failure rate was 24% in the PSM group and 8.3% in the NSM group (pZ 0.029). The biochemical
recurrence-free survival was found as 76% in the PSM group and 91.7% in the NSM group. The differ-
ence between the groups was not statistically significant (pZ 0.06). The overall survival was 100%
in both groups. The surgical margins of the radical prostatectomy material is an important patho-
logical indicator for biochemical failure at mid long-term follow-up. We did not find any effect of
PSM on overall survival or biochemical recurrence-free survival.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.declare no conflicts of interest.
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Effect of positive surgical margins on biochemical failure 511Introduction
Radical prostatectomy (RP) provides perfect disease con-
trol in the majority of patients with clinically localized
prostate cancer (CaP). However, about half of the patients
eventually experience serum prostate-specific antigen
(PSA) elevations without any clinical or radiological evi-
dence of disease metastasis after RP [1]. The actual inci-
dence, clinical significance, and natural history of
biochemical failure (BF) remain unclear. A number of fac-
tors have been reported to be associated with BF after RP,
such as positive surgical margins (PSMs) [2,3]. The rates of
PSM have been reported between 14% and 46% in the
literature [4e6].
Recently, PSA, pathological Gleason score, and PSM have
been reported as the best prognostic factors that predict the
recurrence risk after curative RP [7]. A number of studies
have shown that PSM is a poor prognostic factor after RP
[1,8e10], whereas others claim the opposite [7,11].
In this study, our aim was to investigate the median long-
term effects of PSM and other prognostic factors on
biochemical recurrence-free survival, overall survival, and
BF in patients who underwent RP.Table 1 Comparison of age, preoperative PSA, follow-up
time, and clinical and pathological stages between the
groups.
PSM (n Z 25) NSM (n Z 96) p
Age (y) 67 (58e79) 69 (54e79) 0.89
Preoperative PSA 10.5 (3.2e39) 8.3 (1,1e41) 0.045
Follow-up
time (mo)
46.6 (12e72) 48.3 (7e149) 0.59
cT1c 12 (48) 67 (69.8) 0.05*
cT2a 10 (40) 21 (21.9)
cT2b 3 (12) 8 (8.3)
pT2a 2 (8) 42 (43.8) 0.0001*
pT2b 3 (12) 38 (39.6)
pT2c 9 (36) 8 (8.3)
pT3a 8 (32) 7 (7.2)
pT3b 3 (12) 1 (1)
Data are presented as n (%) or n (range).
NSM Z negative surgical margins; PSA Z prostate-specific an-
tigen; PSM Z positive surgical margins.
*Statistically significant.Methods
After obtaining Institutional Review Board approval (date:
March 8, 2006; August 3, 2012, Number 417), we retro-
spectively evaluated the data of 186 patients who had RP in
our clinic due to clinically localized CaP between March
2006 and August 2012. The patients were evaluated in the
outpatient clinic of Ankara Training and Research Hospital,
Department of Urology. A total of 65 patients who were lost
from the follow-up or with missing data were excluded. The
remaining 121 patients were included in the study.
The diagnosis was achieved by prostate biopsies [per-
formed because of elevated PSA levels (>4 ng/mL) and/or
abnormal digital rectal examination findings]. The
preferred surgical technique was open retropubic nerve-
sparing RP. The patients were divided into two groups:
those with PSM and those with negative surgical margin
(NSM).
We analyzed the age, clinical and pathological stages,
pre- and postoperative Gleason scores, duration of the
follow-up, adjuvant chemo/radiotherapy, BF, biochemical
recurrence-free survival, and overall survival in these pa-
tients. The overall survival was calculated by subtracting
the date of diagnosis from the time of death due to any
cause.
Biopsy and surgical Gleason scores were determined.
The clinical stage was determined using the 2002 TNM
staging systems. PSM was defined as the presence of any
neoplastic cells at the surgical margins, and observation of
cancer cells outside the prostatic capsule was defined as
the extracapsular spread.
According to the international consensus, recurrent
cancer may be defined after two consecutive PSA values of
0.2 ng/dL following radical retropubic prostatectomy
[8,12]. Therefore, we accepted a PSA value 0.2 ng/mL for
the presence of the biochemical recurrence.The follow-up visits were done at postoperative 3rd
month, 6th month, and 12th month, and every 6 months
thereafter until postoperative Year 3 is completed. Then,
digital rectal examination was performed annually together
with serum PSA and/or bone scan.
The data were analyzed using SPSS version 15 (SPSS Inc.,
Chicago, IL, USA). The differences between independent
groups regarding continuous variables were evaluated using
the ManneWhitney U test. For categorical comparisons,
Chi-square or Fisher’s exact test were used whenever
convenient. Biochemical recurrence-free survival was
calculated using KaplaneMeier analysis. The statistical
significance was set at p < 0.05.Results
PSM was found in 25 (20%) patients, whereas 96 patients
had NSM. The median ages of the patients in PSM and NSM
groups were 67 years (58e79 years) and 69 years (54e79
years), respectively (pZ 0.89). The median follow-up time
was 46.6 months (range 12e72 months) for the PSM group
and 48.3 months (range 7e149 months) for the NSM group,
without any statistically significant difference in between
(p Z 0.59). The comparative data of the groups are pre-
sented in Table 1.
The BF rate was 24% in the PSM group and 8.3% in the
NSM group (p Z 0.029; Table 2). The biochemical
recurrence-free survival was found as 76% for the PSM group
and 91.7% for the NSM group. The difference between the
groups was not statistically significant (p Z 0.06; Fig. 1).
The overall survival was 100% in both groups.
Postoperative pathological stage was T3 in 11 (44%) pa-
tients with PSMs and in eight (8.3%) patients with NSMs.
According to these data, PSM is related to postoperative
pathological stage (p < 0.01; Table 1). The BF rates ac-
cording to clinical and pathological stages are presented in
Table 3.
Table 2 Biochemical failure and its relationship with
surgical margin status.
n BFþ BF p
PSM 25 6 (24) 19 (76) 0.029*
NSM 96 8 (8.3) 88 (91.7)
Data are presented as n (%).
BF Z biochemical failure; NSM Z negative surgical margins;
PSM Z positive surgical margins.
*Statistically significant.
Table 3 Clinical and pathological stages in patients with









T2a 10 (40) 2 (8)
T2b 3 (12) 3 (12)
T2c 9 (36) 2 (8)
T3a 8 (32) 3 (12)
T3b 3 (12) 1 (4)
Total 25 (100) 25 (100) 6 (24)
Data are presented as n (%).
512 E. Huri et al.In our study, one patient with stage pT2c plus PSM
received short-term adjuvant hormone therapy (HT;
luteinizing-hormone-releasing-hormone agonists). Another
patient with stage pT2c plus PSM underwent radiotherapy
(RT). Three patients with stage pT3b plus PSM received HT,
and one patient with stage pT3b and PSM received both HT
and RT. One patient with pT3a plus PSM underwent RT and
three patients with pT3a plus extended PSM received HT.
The outcomes of these patients according to biochemical
recurrence are indicated in Table 4. Four patients who had
pathological stage T3 and did not take adjuvant therapy did
not have any biochemical recurrence after a mean follow-
up period of 39 months.
Discussion
Radical retropubic prostatectomy is the most commonly
used definitive treatment modality for clinically localized
CaP [13]. The incidence of PSM has been reported between
14% and 46% after RP in patients with clinically localized
CaP [5,6]. PSM is highly correlated with BF and presence of
local and systemic recurrence [14,15]. This is why RP must
aim for the removal of all prostatic tissues without leaving
any tumor behind.
In the long term, a considerable percentage of the pa-
tients who underwent RP (20e30%) show BF, which is an
indication of cancer recurrence [12,14,16e19]. WeFigure 1. There is no difference between the positive sur-
gical margin and negative surgical margin biochemical
recurrence-free survival curves according to the survival plot
(KaplaneMeier).determined BF in 14 (11.5%) patients in our study, and this
ratio is lower when compared to that reported in the
literature. We can offer appropriate follow-up and treat-
ment options to the patients if we know the probability of
progression and recurrence after surgery.
A number of studies have shown that extracapsular
spread, PSM, high PSA and Gleason score, seminal vesicle
invasion, and lymph node involvement are risk factors for
BF [15,20,21]. In their series with 4490 patients, Budaus
et al. [22] reported that PSA, pT stage, lymph node status,
Gleason score, and PSM were independent prognostic fac-
tors for development of BF after RP. Similarly, in our study
we found a significantly higher BF rate in the PSM group
(p Z 0.029). Similarly, the BF rate was 16% in stage pT3
with PSM and it was 8% in stage pT2 with PSM. Stage pT3
patients represented 16% of the PSM group, whereas the
same stage comprised 8.3% of the NSM group (pZ 0.0001).
The effect of PSM on BF has been debated. Many studies
claimed that PSM following RP affected BF negatively
[1,8e10], whereas others claimed the opposite [7,11].
Following RP, a number of studies have investigated the
prognosis of CaP with BF [1,23]. In addition, PSM does not
always show residual tumor or treatment failure. Simon
et al [24] followed 936 RP patients for 46 months, and found
BF rates of 19% and 7% in the PSM and NSM groups,
respectively. Although the difference was statistically sig-
nificant, the authors stated that a difference of 12% was
smaller than the expected value. Similarly in our study, we
found BF rates of 24% and 8.3% in the PSM and NSM groups,
respectively (p Z 0.029). In another study, Sofer et al [25]
investigated the effects of the number and the sites of PSMTable 4 Evaluation of adjuvant therapy according to






pT3 BR (þ) pT3
BR ()
Adjuvant HT 1 4 2
Adjuvant RT 1 1 1
Total 2 4 (1 patient
had both HTþRT)
3
BR Z biochemical recurrence; HT Z hormone therapy;
RT Z radiotherapy.
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effect on BF, the number of PSM was found as a significant
prognostic factor. By contrast, Nelson et al [26] showed
that not only the tumor volume, but also the site of the
tumor was important for BF.
Akdemir et al [27] evaluated the pathological T stage
and PSM together, and found that patients with stage pT2
and PSM had a similar biochemical prognosis with patients
who had stage pT3a and NSM. The authors stated that the
prognostic effects of PSM and extracapsular invasion were
similar.
The study of Pfitzenmaier et al. [28] showed that PSM
was an important prognostic factor for PSA recurrence,
local recurrence, and distant metastasis. This study showed
that advanced pathological stage and grade increased the
risk of PSM. The authors found higher CaP-specific (8.6% vs.
0.6%) and overall death (17.1% vs. 10.4%) rates in the PSM
group.
In our study, the BF rate was significantly higher in the
PSM group when compared to the NSM group (p Z 0.029),
and this result was in accordance with the literature.
Similarly, the rate of PSM increased as the pathological
stage increased. In a mean follow-up period of 46.6  17.4
months, PSM and pT stage were found to have significant
effects on BF.
Chalfin et al. [29] followed 4461 patients at long term
(median follow-up 10 years) and found that PSM was an
independent prognostic factor for CaP-specific mortality.
By contrast, Boorjian et al. [30] investigated the effect of
PSM on the mortality of CaP on 16,749 patients. The median
follow-up period was 10.6 years, and the authors found that
the number or the site of PSM did not affect mortality.
Similarly in our study, we found that PSM did not affect the
overall survival or biochemical recurrence-free survival in a
mean follow-up period of 46.6  17.4 months. Although
there is a limited number of patients receiving adjuvant HT
or RT among patients with PSM, this condition may posi-
tively affect biochemical recurrence-free survival and
overall survival.
The retrospective design and relatively small patient
number are the limitations of our study. However, it is a
median long-term follow-up study evaluating the relation
of PSM with biochemical recurrence-free survival and
overall survival.
In conclusion, PSM has been found in patients with stage
pT2b or higher. The surgical margins of the RP material is an
important pathological indicator for biochemical recur-
rence at mid long-term follow-up, and it is a significant
finding for foreseeing CaP that extend out of the borders of
the prostate. We did not find any effect of PSM on overall
survival or biochemical recurrence-free survival.
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